North Chicago / Copenhagen – October 05, 2026 -- AbbVie and Genmab A/S reported that epcoritamab combined with standard R-CHOP chemotherapy reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients, based on topline Phase 3 data.

North Chicago, Ill. – – September 28, 2026 -- AbbVie (NYSE: ABBV) has secured U.S. FDA approval for JUVMO (tavapadon), the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease, with commercial availability set for October 2026.

Rockville, Md. – September 24, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) reported that 60% of Dose Level 3 participants with three-year follow-up data in its Phase II ALTITUDE study achieved a greater-than-2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) after a single in-office treatment with investigational gene therapy sura-vec, with no vision-threatening events recorded among responders.

North Chicago, Ill. – September 07, 2026 -- Allergan Aesthetics, an AbbVie company, has released a global study of more than 12,000 beauty-involved consumers across nine markets showing a decisive shift away from one-time aesthetic procedures toward personalized, long-term treatment plans.

North Chicago, Ill. – September 07, 2026 -- Allergan Aesthetics, an AbbVie company, has released a global study of more than 12,000 beauty-involved consumers across nine markets showing a decisive shift away from one-time aesthetic procedures toward personalized, long-term treatment plans.